Overview

Study to Evaluate the Effects of AT-527 in Non-Hospitalized Adult Patients With Mild or Moderate COVID-19

Status:
Completed
Trial end date:
2021-10-13
Target enrollment:
Participant gender:
Summary
This randomized study evaluates the antiviral activity, safety, efficacy and pharmacokinetics of AT-527 versus a placebo in participants with mild or moderate coronavirus disease (COVID-19) who are not hospitalized.
Phase:
Phase 2
Details
Lead Sponsor:
Hoffmann-La Roche
Collaborator:
Atea Pharmaceuticals, Inc.